“PD-L1 Expression as a Predictor of Response to Neoadjuvant Immunotherapy in Triple-Negative Breast Cancer” (2026) Journal of Evidence-Based Medical Research, 2(03), pp. 58–69. doi:10.66687/jebmr.2.03.2026.43.